Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Adma Biologics Inc (NASDAQ: ADMA) closed the day trading at $16.75 down -9.65% from the previous closing price of $18.54. In other words, the price has decreased by -$9.65 from its previous closing price. On the day, 11.89 million shares were traded. ADMA stock price reached its highest trading level at $17.51 during the session, while it also had its lowest trading level at $14.625.
Ratios:
For a better understanding of ADMA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 44.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.80. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 5.33. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5. Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 15 ’25 when Grossman Adam S sold 21,000 shares for $18.66 per share. The transaction valued at 391,860 led to the insider holds 2,037,850 shares of the business.
Grossman Adam S bought 63,000 shares of ADMA for $1,176,840 on Jul 15 ’25. On Jun 16 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $20.81 each. As a result, the insider received 437,010 and left with 2,043,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4426137600 and an Enterprise Value of 4436520960. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.72, and their Forward P/E ratio for the next fiscal year is 18.47. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.43 while its Price-to-Book (P/B) ratio in mrq is 10.07. Its current Enterprise Value per Revenue stands at 9.658 whereas that against EBITDA is 27.738.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.55, which has changed by 0.049498796 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $11.42. The 50-Day Moving Average of the stock is -10.70%, while the 200-Day Moving Average is calculated to be -10.75%.
Shares Statistics:
Over the past 3-months, ADMA traded about 3.11M shares per day on average, while over the past 10 days, ADMA traded about 3763390 shares per day. A total of 239.38M shares are outstanding, with a floating share count of 230.54M. Insiders hold about 3.43% of the company’s shares, while institutions hold 89.36% stake in the company. Shares short for ADMA as of 1752537600 were 14470950 with a Short Ratio of 4.66, compared to 1749772800 on 13806018. Therefore, it implies a Short% of Shares Outstanding of 14470950 and a Short% of Float of 7.4399999999999995.
Earnings Estimates
A comprehensive evaluation of Adma Biologics Inc (ADMA) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.19, with high estimates of $0.19 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.6 and $0.54 for the fiscal current year, implying an average EPS of $0.58. EPS for the following year is $0.93, with 3.0 analysts recommending between $0.97 and $0.87.
Revenue Estimates
3 analysts predict $130.1M in revenue for the current quarter. It ranges from a high estimate of $133.3M to a low estimate of $126.9M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $119.84MFor the next quarter, 3 analysts are estimating revenue of $137.93M. There is a high estimate of $140.5M for the next quarter, whereas the lowest estimate is $133.5M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $509.61M, while the lowest revenue estimate was $502.7M, resulting in an average revenue estimate of $506.05M. In the same quarter a year ago, actual revenue was $426.45MBased on 4 analysts’ estimates, the company’s revenue will be $637.35M in the next fiscal year. The high estimate is $647.21M and the low estimate is $629.4M.
